Key Findings of Roche's DME Long-term Study on Vabysmo
Wednesday, 17 July 2024, 18:13
Key Findings of Roche's DME Long-term Study on Vabysmo
Roche Holding revealed that it successfully met all primary endpoints in the study on Vabysmo.
- Vabysmo showed promising results in the treatment of Diabetic Macular Edema (DME).
- The positive data suggests potential benefits of Vabysmo for patients with DME.
This development underlines Roche's dedication to improving therapies for eye-related conditions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.